Vertex Pharmaceuticals Inc

General

Total Cases22

Active Cases3

Patents385

CourtsD. Delaware E.D. Virginia C.D. California

TypeOperating Company

Elite Ratings

PTAB

vertex-pharmaceuticals

vertex-pharmaceuticals

Ratings

Experience

Grade

Trend

DCT

L1

D

PTAB

L4

A

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
08/30/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Plaintiff's Opening Claim Construction Brief filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) (Entered: 08/30/2024)
08/09/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	JOINT Claim Construction Chart, by Vertex Pharmaceuticals Incorporated. (Attachments: # 1 Exhibit A)(Fahnestock, Derek) Modified on 8/12/2024 (nms). (Entered: 08/09/2024)
07/26/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Plaintiff Vertex Pharmaceuticals Incorporated's Proposed Claim Terms for Construction With Respect to U.S. Patent No. 11,752,106 - filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) (Entered: 07/26/2024)
07/26/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc's Disclosure of Claim Terms and Preliminary Construction with Respect to the '106 Patent filed by Lupin Limited, Lupin Pharmaceuticals, Inc..(Murphy, Francis) (Entered: 07/26/2024)
07/12/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc.'s Initial Invalidity Contentions with Respect to US Patent No. 11,752,106 filed by Lupin Limited, Lupin Pharmaceuticals, Inc..(Murphy, Francis) (Entered: 07/12/2024)
06/28/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Plaintiff Vertex Pharmaceuticals Incorporated's Initial Disclosures Under Paragraph 4(c) of the District of Delaware Default Standard for Discovery With Respect to U.S. Patent No. 11,752,106 - filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) (Entered: 06/28/2024)
06/21/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	ANSWER to 67 Answer to Complaint, Counterclaim (with respect to U.S. Patent No. 11,752,106), by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) Modified on 6/24/2024 (nms). (Entered: 06/21/2024)
06/07/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of (1) Plaintiff Vertex Pharmaceuticals Incorporated's Initial Disclosures Under Paragraph 4(a) of the District of Delaware Default Standard for Discovery With Respect to U.S. Patent No. 11,752,106 and (2) Plaintiff Vertex Pharmaceuticals Incorporated's Second Amended Initial Disclosures Under Federal Rule of Civil Procedure 26(a)(1) and Paragraph 3 of the Delaware Default Standard for Discovery - filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) (Entered: 06/07/2024) NOTICE OF SERVICE of (1) Plaintiff Vertex Pharmaceuticals Incorporated's Initial Disclosures Under Paragraph 4(a) of the District of Delaware Default Standard for Discovery With Respect to U.S. Patent No. 11,752,106 and (2) Plaintiff Vertex Pharmaceuticals Incorporated's Second Amended Initial Disclosures Under Federal Rule of Civil Procedure 26(a)(1) and Paragraph 3 of the Delaware Default Standard for Discovery - filed by Vertex Pharmaceuticals Incorporated.(Fahnestock, Derek) (Entered: 06/07/2024)
06/07/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE OF SERVICE of Lupin Limited and Lupin Pharmaceuticals, Inc's Second Amended Federal Rule of Civil Procedure 26(a)(1) Initial Disclosures filed by Lupin Limited, Lupin Pharmaceuticals, Inc..(Murphy, Francis) (Entered: 06/07/2024)
06/07/24	Vertex Pharmaceuticals Inc v. Lupin Ltd 1:22-CV-00966 ( D. DE )	NOTICE of Lupin Limited and Lupin Pharmaceuticals, Inc's Second Amended initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery by Lupin Limited, Lupin Pharmaceuticals, Inc. (Murphy, Francis) (Entered: 06/07/2024)